Format

Send to

Choose Destination
J Biomed Sci. 2018 Mar 13;25(1):23. doi: 10.1186/s12929-018-0427-3.

Long non-coding RNA MIAT in development and disease: a new player in an old game.

Author information

1
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, No.246 XueFu Avenue, Harbin, Heilongjiang Province, China.
2
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, No.246 XueFu Avenue, Harbin, Heilongjiang Province, China. xmjiang@hrbmu.edu.cn.
3
Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, No.246 XueFu Avenue, Harbin, Heilongjiang Province, China. yfcui777@hotmail.com.

Abstract

BACKGROUND:

Long non-coding RNAs (lncRNAs), which are a portion of non-protein-coding RNAs (ncRNAs), have manifested a paramount role in the pathophysiology of human diseases, particularly in pathogenesis and progression of disease. Myocardial infarction associated transcript (MIAT), which was recently found to demonstrate aberrant expression in various diseases, such as myocardial infarction, schizophrenia, ischemic stroke, diabetic complications, age-related cataract and cancers, is a novel disease-related lncRNA. This work summarize current evidence regarding the biological functions and underlying mechanisms of lncRNA MIAT during disease development.

SHORT CONCLUSION:

LncRNA MIAT likely represents a feasible cancer biomarker or therapeutic target.

KEYWORDS:

Diseases; LncRNA; Long non-coding RNA; MIAT

PMID:
29534728
PMCID:
PMC5851271
DOI:
10.1186/s12929-018-0427-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center